|
Keymnneomygop
Post on: 03-07-2008
|
[color=#000099][url=http://www.drugs.com/news]LONDON, June 20, 2008-The European Medicines[/url] power (EMEA) has recommended updating the result intelligence for epoetin-containing medicines with a new threat for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patints pain cancer.
Epoetin-containing medicines are indicated in patients with persistent [url=http://www.blogotop.com/achetercialis]achat viagra[/url] incompetent and for the treatment of anaemia in symptomatic patients with non-myepoid growths receivjng chemotherapy. The instrumentality’s board for sanative Products for sympathetic Use (CHMP) had rehjashinged new details from studies that showed an increased hazard of sarcoma [url=http://www.blogotop.com/achetercialis]acheterlevitra generique[/url] development, venous thromboembolism and shorter all-
inclusive [url=http://www.google.com/search?hl=en&q=survival+in+cancer+patients&btnG=Google+Search]survival in cancer patients[/url] who admitd epoetins compared to patients who did not clear them. Following this notice, the CHMP concluded, at its June 2008 union, that the emolumentss of epoetins persist [url=http://asmforum.fr/index.php?showuser=6911]acheter cialis[/url] surpass their hazards in the approved indications. after all, in cancer patients with a reasonably covet enthusiasm-expectanyc, the gain of using epoetins does not surpass the hazard [url=http://www.blogotop.com/achetercialis]acheter viagra[/url] growth
ascension and shorter inclusive survival and consequently the cabinet concluded that in these patients anaemia should be corrected with blood yransfusions.. [/color]
|
